Inspire vs UPPP for
Sleep Apnea

Inspire Upper-Airway Stimulation

The effectiveness of Inspire is documented by the STAR trial: at 12 months, median AHI fell from 29.3 to 9.0 events per hour (Strollo et al., New England Journal of Medicine, 2014). At five years, 75% of patients who completed a follow-up sleep study still met response criteria, showing that results are durable over time (Woodson et al., Otolaryngology–Head and Neck Surgery, 2018).

Current FDA labeling approves Inspire for adults with an AHI of 15-100 events per hour and a BMI up to 40. Response may decrease at higher BMI, and insurance coverage criteria may be stricter than FDA labeling. A Drug-Induced Sleep Endoscopy (DISE) is required before implantation: a finding of complete concentric collapse (CCC) at the palate excludes Inspire candidacy because the nerve stimulation cannot reliably open that collapse pattern.

Because Inspire is a neurostimulator implanted under the skin of the upper chest, it removes no palate or throat tissue. The device can be explanted if needed, but removal is itself a surgical reoperation, and it is not trivial (documented in FDA MAUDE adverse-event reviews). Most patients find the implant to be low-burden: it is activated with a small remote at bedtime and requires no mask or machine.

UPPP (Uvulopalatopharyngoplasty)

UPPP removes or repositions the soft palate, uvula, and sometimes tonsillar tissue to enlarge the retropalatal airway. In a randomized controlled trial (Browaldh et al., Thorax, 2013), mean AHI fell from 53.3 to 21.1 events per hour (note that this cohort had higher baseline severity, so these figures are not a direct head-to-head comparison with the Inspire STAR-trial numbers above).

UPPP is a reasonable option for select patients with palatal-level anatomy and can even be staged with or combined with Inspire in some cases (Steffen et al., Laryngoscope, 2019). Tissue removal is permanent, and recovery typically involves significant throat soreness for approximately two weeks.

For patients whose sleep apnea comes with large tonsils, less surgery may do as much. In the TEAMUP randomized trial (Sundman et al., JAMA Otolaryngology–Head & Neck Surgery, 2022) of 93 adults with large tonsils and moderate to severe OSA, mean AHI fell from 56.9 to 24.7 events per hour after tonsillectomy alone and from 51.0 to 28.0 after modified UPPP. The difference between the two was small, and the authors concluded that tonsillectomy alone could be considered as the less extensive alternative in this group.

A multicenter analysis using the ADHERE registry compared upper-airway stimulation to traditional airway surgery (including UPPP) across a large patient population. Postoperative AHI was approximately 10 events per hour for upper-airway stimulation versus 15 for surgery, with a higher rate of Sher-defined surgical success (postoperative AHI <20 AND ≥50% reduction from baseline) for stimulation (Huntley et al., Annals of Otology, Rhinology & Laryngology, 2021).